Alnis LLC
This article was originally published in Start Up
Executive Summary
Alnis is using molecular building blocks to shape themselves around a target molecule into a molecular mold, both protecting delicate therapeutics and helping to target them to the right tissues.
You may also be interested in...
Broad, Broader, Broadest: Drug Delivery Start-Ups
Drug delivery start-ups abound, despite the harsh environment for new biopharmaceutical companies. Drug delivery deals are increasing, as are relatively highly valued acquisitions, as larger drug delivery or service companies seek to broaden their tool kits. But for companies who haven't yet proven themselves, dealmaking is difficult in a variety of ways. Credibility is tough to achieve.
Women's Health: Too early or Too Late?
As an industry, women's health is in its infancy. It has yet to develop beyond a collection of niche specialties in reproductive medicine and breast cancer.
EPIcyte Pharmaceutical Inc.
EPIcyte has licensed patents from the Scripps Research Institute covering new methods of human antibody production in plants that can lower costs up to 100 fold. The company is also developing proprietary products based on its technology, initially, an anti-herpes prophylactic and a contraceptive based on an anti-sperm antibody.